Roger Dansey
About Roger Dansey
Roger Dansey, M.D., is a non-employee director of Nurix Therapeutics appointed on November 6, 2025, and serves on the Board’s Clinical and Commercialization Committee . He holds an M.D. from the University of the Witwatersrand (Johannesburg, South Africa) and has over two decades of hematology/oncology drug development and commercialization leadership across Pfizer, Seagen, Merck, Gilead, and Amgen . His appointment adds late-stage oncology development, registration, and launch expertise aligned with Nurix’s pivotal BTK degrader program .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Pfizer Oncology | Chief Development Officer and Chief Oncology Officer | Jan 2024 – Mar 2025 | Led oncology development; retired Mar 2025 |
| Seagen | President, R&D | Nov 2022 – Dec 2023 (through Pfizer acquisition) | R&D leadership through acquisition |
| Seagen | Interim CEO | May 2022 – Nov 2022 | Executive leadership transition |
| Seagen | Chief Medical Officer | May 2018 – May 2022 | Oversaw clinical strategy and development |
| Merck & Co. | Therapeutic Area Head, Late-Stage Oncology | Prior role (dates not disclosed) | Led registration efforts for Keytruda across multiple tumor types |
| Gilead Sciences | Vice President, Oncology Clinical Research | Prior role (dates not disclosed) | Oncology development leadership |
| Amgen | Global Development Lead for Xgeva (denosumab) | Prior role (dates not disclosed) | Asset development leadership |
| Karmanos Cancer Institute/Wayne State University | Associate Professor of Hem/Onc | Prior role (dates not disclosed) | Academic clinical leadership |
External Roles
| Organization | Role | Public/Private | Notes |
|---|---|---|---|
| Bicycle Therapeutics plc | Director | Public | Current directorship |
| Inovio Pharmaceuticals, Inc. | Director | Public | Current directorship |
| MycRX Pharma | Director | Private | Current directorship |
| Ottimo Pharma Ltd | Director | Private | Current directorship |
| Shasqi Inc. | Director | Private | Current directorship |
Board Governance
- Independence and status: Appointed as a non-employee director; Board disclosed no arrangements for selection, no family relationships, and no related-party interests under Item 404(a) at appointment, consistent with independence under Nasdaq rules, though a formal independence determination was not separately stated in the 8-K .
- Committee assignment: Clinical and Commercialization Committee (CCC) member . CCC remit includes oversight of clinical development and commercialization programs; R&D platform and pipeline; trial safety and commercial strategy; healthcare compliance; IP strategy; market access and pricing; and competitive scientific developments .
- Tenure: Class III director with term expiring at the 2026 annual meeting .
- Attendance: For FY2024 (pre-appointment), none of Nurix’s directors attended fewer than 75% of Board and committee meetings, indicating a culture of engagement; Dansey’s attendance will be reportable in future proxies .
Fixed Compensation
| Component | Policy/Amount | Dansey-specific 2025 Treatment |
|---|---|---|
| Annual cash retainer (Board) | $50,000 per non-employee director | Pro rata for remainder of FY2025 |
| Committee member retainer (CCC) | $7,500 annually (CCC member) | Pro rata for remainder of FY2025 |
| Meeting fees | None disclosed (retainer-based) | N/A |
| Indemnification | Standard indemnification agreement entered | Executed |
Performance Compensation
| Equity Type | Grant Size/Timing | Vesting/Term | Exercise Price | Acceleration |
|---|---|---|---|---|
| Initial Stock Option | 50,000 options granted at appointment (11/6/2025) | Vests monthly over 3 years; 10-year term (per program) | Closing sale price on grant date (11/6/2025) | Full acceleration upon a Corporate Transaction under the 2020 EIP |
| Annual Stock Option | 25,000 options at each annual meeting while in service | Vests on earlier of next annual meeting or 1 year | Fair market value on grant date | Full acceleration upon a Corporate Transaction |
Notes: Nurix’s non-employee director program is option-centric; no performance share units are disclosed for directors. The company maintains a clawback policy applicable to officers and additional covered employees for incentive-based compensation, but the policy’s scope does not expressly extend to non-employee directors; insider policy prohibits hedging and restricts pledging without pre-approval .
Other Directorships & Interlocks
| Area | Detail |
|---|---|
| Public company boards | Bicycle Therapeutics plc; Inovio Pharmaceuticals, Inc. |
| Potential interlocks/conflicts | No Item 404(a) related-party transactions or family relationships disclosed at appointment. Nurix maintains Audit Committee oversight of related-party transactions and a governance framework for conflicts . |
| Partner overlap context | Nurix collaborates with Pfizer on degrader antibody conjugates (DAC). Dansey retired from Pfizer in March 2025; the 8-K indicates no related-party interest at appointment . |
Expertise & Qualifications
| Qualification | Evidence |
|---|---|
| Oncology clinical development leadership | Led late-stage oncology at Merck (Keytruda registrations) |
| Biopharma R&D and CMO experience | Seagen CMO (2018–2022), President R&D (2022–2023) |
| Large-cap oncology portfolio oversight | Pfizer Oncology CDO/Chief Oncology Officer (2024–2025) |
| Academic and hematology/oncology background | Associate Professor, Karmanos Cancer Institute; M.D., University of the Witwatersrand |
| Commercialization insight | Asset registration/launch leadership (Keytruda; Xgeva) |
| Fit with NRIX CCC remit | Oversight of clinical, commercial strategy aligns with CCC responsibilities |
Equity Ownership
| Item | Status/Detail |
|---|---|
| Initial beneficial ownership (Form 3) | Filed Nov 10, 2025; “No securities are beneficially owned” reported at filing |
| Initial option award | Option to purchase 50,000 shares granted Nov 6, 2025; vests monthly over 3 years |
| Annual option cadence | Eligible for 25,000 option at each annual meeting while serving |
| Hedging/pledging | Hedging prohibited; pledging generally prohibited without pre-approval under Insider Trading Policy |
Insider Filings and Transactions
| Date | Form | Summary | Holdings Reported |
|---|---|---|---|
| 11/10/2025 | Form 3 | Initial statement of beneficial ownership filed upon appointment | “No securities are beneficially owned.” |
| 11/06/2025 | Board action (disclosed in 8-K) | Initial stock option grant for 50,000 shares; pro rata cash retainers; CCC membership | Grant and terms disclosed; strike = closing price on 11/6/2025 |
Governance Assessment
-
Positives
- Deep, highly relevant oncology development and registration experience directly aligned with Nurix’s transition to pivotal studies and commercialization planning for its BTK degrader .
- Committee placement (Clinical and Commercialization Committee) leverages his strengths in clinical strategy, commercial planning, and competitive landscape assessment .
- Non-employee status with no related-party transactions or familial ties disclosed at appointment; standard indemnification in place .
- Director compensation structure mixes modest cash retainers with multi-year vesting options, promoting alignment with long-term shareholder value .
-
Watch items
- Multiple outside directorships in oncology-adjacent companies may create information-flow sensitivities; Nurix’s related-party and conflict policies, Audit Committee oversight, and Code of Conduct govern conflicts and disclosures (no Item 404(a) related-party transactions disclosed at appointment) .
- Single-trigger acceleration of director option awards upon a Corporate Transaction may be viewed by some investors as less stringent than double-trigger constructs; disclosed in 8-K .
- Attendance and engagement will be monitorable beginning with the FY2025/2026 proxy; Board historically shows strong attendance (≥75% for all directors in FY2024) .
-
Overall view: Dansey brings high-caliber late-stage oncology and commercialization expertise that strengthens NRIX’s board effectiveness in pivotal execution and launch readiness, with current filings showing no conflicts or related-party exposures and a compensation structure geared toward equity-based alignment .